Aside from ICIs, new therapeutic approaches target tumor-specific antigens (TSA: antigens only expressed by tumor cells) and tumor-associated antigens (TAA: antigens overexpressed by tumor cells but also expressed by healthy cells) such as glypican-3 (GPC3) or alpha-fetoprotein (AFP). This evidence concerns the gene AFP and neoplasm.